Express Scripts Holding Co. grew its second-quarter profit by 21% even though the pharmacy benefit management company filled fewer prescription drug claims for its customers.
Drugmaker Gilead Sciences saw its earnings fall again amid lower sales of its expensive blockbuster hepatitis C drug Harvoni.
Roughly 100 national and state medical societies are backing a bill that would exempt drug and device makers from have to report payments made to doctors for participating in continuing medical education or receiving textbooks, journals and educational materials related to CME.
History buffs and infectious-disease experts have already drawn links between the rubella outbreak in the 1960s and the current spread of Zika. But drugmakers today face greater regulatory hurdles, and the federal government has yet to dedicate funding to address the Zika epidemic.
Pharmaceutical giant AstraZeneca failed to block approval of generics for its best-selling cholesterol drug after a federal judge tossed out the company's request.
Patient advocates say a bill passed by Congress last week that ostensibly decriminalizes drug addiction will no doubt open doors for those seeking treatment. But others say the legislation is a lost opportunity to strengthen the country's ability to track opioid prescriptions.
Nearly every U.S. governor pledged Wednesday to combat the opioid crisis that is leaving a trail of overdose deaths and misery in their states.
Juno Therapeutics and its CEO, Hans E. Bishop, are being named in a lawsuit over whether the biotechnology company misled investors about the death of a patient in a key study involving its drug intended to treat leukemia.
The HIV-prevention medication PrEP could help slash rates of infection, save hundreds of thousands of dollars in individual healthcare costs and save lives. Now, Washington, D.C., which has one of the highest rates of HIV infection in the U.S., is launching a campaign to bring light to this option.
AbbVie's Humira, the second-biggest selling drug in the world, could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat some inflammatory diseases.
Amgen is bracing for yet another drug to compete with its biologic medications. An FDA advisory panel is scheduled to consider approval Wednesday of a biosimilar created by Sandoz, Novartis' generic arm. The panel will advise the FDA, which makes the final call.
Shares of Juno Therapeutics plunged more than 27% Friday, a day after halting a midstage study on a potential leukemia treatment following two patient deaths.